Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03090581
Other study ID # CB JKMT-1
Secondary ID
Status Recruiting
Phase N/A
First received March 8, 2017
Last updated March 27, 2017
Start date March 15, 2017
Est. completion date March 2018

Study information

Verified date March 2017
Source Hospital Universitari Vall d'Hebron Research Institute
Contact Karina I Loor, MD
Phone 93 274 6138
Email kloor@vhebron.net
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The survival of lung transplant patients (PD) is limited mainly by Infections, graft dysfunction in the immediate postoperative period and chronic dysfunction. Up to 36% have an episode of acute rejection after transplantation. For the diagnosis of these pathologies, transbronchial lung biopsy (BPTB) is essential. The classical method is the realization of BPTB with conventional clamp, but the performance diagnosis is limited. However, the use of cryoprobes for sampling in other pulmonary pathologies have been shown to achieve a higher diagnostic yield. The BPTB performance is variable and depends on factors such as sample size and the presence of artifacts (crushing) produced by the forceps tweezers. The objective principal is to compare the diagnostic yield of samples obtained with cryoprobe compared to those obtained with conventional biopsy tweezers. A prospective, randomized, and comparative study is proposed for all patients in the intensive care unit after lung transplantation in a 24-month period, at Vall de Hebron Hospital. Patients will be divided into two groups: symptomatic and asymptomatic. The exclusion criteria are the contraindications of the procedure and the factors which increase the hemorrhagic risk. A flexible bronchoscope (BF-18BS) will be used and the procedure will be performed according to the technique conventional. The patient undergoing the procedure will be intubated, sedated and relaxed under supervision and continuous monitoring by an intensivist. A bronchoalveolar lavage and a maximum of 6 samples will be obtained. Morphological study (middle area, artifacts, components, diagnosis), microbiological, histological and anatomopathological according to the usual protocol. The duration of the procedure, the complications and the frequency with which the diagnosis obtained after the procedure modifies the therapeutic behavior will be monitored. These data will allow to evaluate the potential benefits of this procedure in the diagnosis of pulmonary pathology in lung transplantation.


Description:

Bronchoscopic examinations will be performed with intubated patients under continuous monitoring (pulse oximetry, blood pressure, heart and respiratory rate), Oxygen therapy with high flows and surveillance by anesthesiologist. The bronchopulmonary lobe where the biopsies will be performed is determined prior to the procedure based on an imaging study (chest x-ray or computed tomography). Transbronchial biopsies will be obtained using a flexible bronchoscope (Pentax, 3.2 mm working channel), which approaches the subsegment where the affected area is located. The 2.4 mm diameter cryoprobe is placed (Erbokryo®), and moves forward until it encounters a soft resistance. The cryoprobe is removed between 5-10 mm and the freezing is applied for 3 seconds. After 3 seconds, the probe is gently removed together with the bronchoscope and frozen tissue sample at the tip of the probe. In the case of strong resistance, the process is stopped and then repeated. In the case of the use of forceps, the conventional technique is used.


Recruitment information / eligibility

Status Recruiting
Enrollment 132
Est. completion date March 2018
Est. primary completion date January 2018
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Pulmonary transplant patients admitted to the intensive care unit who are assigned a transbronchial lung biopsy.

Exclusion Criteria:

- Respiratory insufficiency refractory to oxygen therapy.

- Acute or subacute ischemic heart disease.

- Severe arrhythmias.

- Coagulation disorders: platelets < 60,000-50,000 or Prothrombin time > 60%.

- Lack of informed consent.

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Biopsies CP
Transbronchial biopsies will be obtained with a flexible bronchoscope, using a cryoprobe.
Biopsies FC
Transbronchial biopsies will be obtained with a flexible bronchoscope, using a forceps.

Locations

Country Name City State
Spain Hospital Vall de Hebron. Barcelona Catalonia

Sponsors (1)

Lead Sponsor Collaborator
Hospital Universitari Vall d'Hebron Research Institute

Country where clinical trial is conducted

Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of patients in whom a pathological diagnosis is obtained after obtaining transbronchial biopsies, performed with forceps or cryosondes. Graft rejection is classified according to the criteria of the International Society for Heart and Lung Transplantation (ISHLT) in 2007. 5 days after biopsies
Secondary Number of alveoli, bronchioles, bronchi, blood vessels and pleura containing each biopsy. A microscope will be used with Software Mese. ¨Leica Application Suite X¨. 5 days after biopsies
Secondary Number of complications related to the procedure. Complications: bleeding, pneumothorax, infection or acute respiratory failure. 30 days after biopsies
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT06309628 - Analysis of Volatile Organic Compounds in the Breath of Lung Transplant Rejection Patients Using Infrared Spectroscopy
Withdrawn NCT02893176 - Macitentan in the Treatment of Organ Rejection After Lung Transplantation Phase 4
Completed NCT02441413 - Transplant Optimization Using Functional Imaging (TROFI) N/A
Recruiting NCT05375149 - Exhaled Breath Particles in Lung Transplantation
Active, not recruiting NCT03967340 - PREdiction of Chronic LUng Allograft Dysfunction
Active, not recruiting NCT05260372 - Next Generation Sequencing to Detect Acute Rejection in Lung Transplant Patients.
Recruiting NCT06082037 - A Study to Test How Effective Belumosudil Tablets Are for Treating Adult Participants With Chronic Lung Allograft Dysfunction Phase 3
Recruiting NCT04714801 - Adipose Derived Mesenchymal Cell Treatment in Lungtransplantation Phase 1/Phase 2
Active, not recruiting NCT05170425 - LAMBDA 002 (Lung Registry) Study
Completed NCT02474927 - Combination Therapy With Carfilzomib for the Antibody-Mediated Rejection Diagnosis in Lung Transplantation Phase 2
Recruiting NCT05006742 - Comparison of Transbronchial Cryobiopsy and Forceps Biopsy in Lung Transplant Recipients N/A
Recruiting NCT02812290 - Diagnostic and Therapeutic Applications of Microarrays in Lung Transplantation
Not yet recruiting NCT03500575 - Extracorporeal Photopheresis in Lung Transplant Rejection for Cystic Fibrosis (CF) Patients N/A
Withdrawn NCT03805178 - Lung Transplant Plasmapheresis/Belatacept/Carfilzomib for Antibody Mediated Rejection and Desensitization Phase 2
Completed NCT03359863 - Pirfenidone for Restrictive Chronic Lung Allograft Dysfunction Phase 2
Active, not recruiting NCT03656926 - Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Single Lung Transplant (BOSTON-2) Phase 3
Completed NCT01985412 - Genome Transplant Dynamics: Non-invasive Sequencing-based Diagnosis of Rejection
Completed NCT04234919 - Longitudinal Study of Cell Free DNA in Lung Transplant
Recruiting NCT04837339 - Diagnostic and Prognostic Biomarkers of Transplant Dysfunction in the Context of Lung Transplantation N/A
Recruiting NCT06112951 - A Prospective Randomized Trial of ECP in Subclinical AMR N/A